Chemical inhibitors of CYP2D34 include a range of compounds that directly bind to the active site of the enzyme, thereby obstructing its normal metabolic function. Quinidine, for instance, is known for its ability to competitively bind to CYP2D34, effectively preventing the metabolism of substrates that would normally occur. Similarly, Fluoxetine occupies the active site of CYP2D34, which inhibits the enzyme's function by precluding substrate interaction. Paroxetine operates on the same principle, binding to the active site and impeding the normal enzymatic activity that would typically facilitate substrate metabolism. Methadone interacts with CYP2D34 at the active site as well, which leads to a reduction in the enzyme's activity and subsequent decrease in substrate processing.
Ritonavir is another inhibitor that targets CYP2D34, binding directly to the enzyme and interfering with its characteristic metabolizing activities. Haloperidol decreases the catalytic efficiency of CYP2D34 through direct inhibition at the enzyme's active site, which alters its normal function. The action of Diphenhydramine and Chlorpheniramine as competitive inhibitors allows them to reduce the metabolic capacity of CYP2D34 by occupying the same site that the substrates would normally bind to. Codeine competes with endogenous substrates for binding at CYP2D34's active site, resulting in diminished enzymatic activity and a consequent decrease in metabolism. Dextromethorphan also inhibits the normal metabolic activity of CYP2D34 by engaging with the enzyme's active site, preventing the usual metabolic processing. Bufuralol and Ajmalicine both perform their inhibitory actions through similar mechanisms, competitively engaging with the active site of CYP2D34, which blocks substrate interaction and reduces the overall activity of the enzyme. Each of these chemicals demonstrates a direct inhibitory effect on CYP2D34 by specific interactions at its active site, leading to an overall decrease in the enzyme's ability to process its substrates.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Quinidine | 56-54-2 | sc-212614 | 10 g | $102.00 | 3 | |
Inhibits CYP2D34 by competitively binding to the enzyme's active site, preventing substrate metabolism. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $312.00 | 9 | |
Occupies the active site of CYP2D34, directly inhibiting its metabolic function. | ||||||
Paroxetine | 61869-08-7 | sc-507527 | 1 g | $180.00 | ||
Binds to the CYP2D34 active site, impeding the enzyme's ability to metabolize its substrates. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $122.00 | 7 | |
Binds to CYP2D34, interfering with substrate metabolism characteristic of the enzyme. | ||||||
Haloperidol | 52-86-8 | sc-507512 | 5 g | $190.00 | ||
Decreases the catalytic efficiency of CYP2D34 by direct inhibition at the enzyme's active site. | ||||||
Diphenhydramine hydrochloride | 147-24-0 | sc-204729 sc-204729A sc-204729B | 10 g 25 g 100 g | $51.00 $82.00 $122.00 | 4 | |
Competitively inhibits CYP2D34 by occupying the active site, preventing normal enzymatic activity. | ||||||
Dextromethorphan | 125-71-3 | sc-278927 sc-278927A sc-278927B | 10 g 100 g 500 g | $174.00 $1133.00 $5106.00 | 3 | |
Inhibits normal substrate metabolism by CYP2D34 through binding to the enzyme's active site. | ||||||